• Stelios Fotiou, Tserkezoglou Aliki, Zarganis Petros, Stauropoulou Ioanna, Velentzas Konstantinos, Michalaki Vasiliki, and Creatsas George.
• 2nd Department of Obstetrics and Gynecology, University of Athens, School of Medicine, Aretaieion Hospital, Athens 11528, Greece. Geocre@aretaieio.uoa.gr
• Gynecol. Oncol. 2009 Aug 1; 114 (2): 178-82.

ObjectivesTo evaluate the role of secondary cytoreductive surgery in the management of patients with isolated nodal recurrence of epithelial ovarian cancer.MethodsIn this retrospective study, the data of 21 patients submitted to secondary cytoreductive surgery for isolated nodal recurrence were reviewed. All clinical characteristics at initial treatment and relapsing disease, operative and pathologic data of secondary cytoreduction and follow-up information were abstracted from the files and evaluated.ResultsMedian age at initial treatment was 50 years; 15 patients (71%) had FIGO stage III/IV disease. Following primary surgical and systematic treatment, isolated nodal recurrence was diagnosed after a median DFI of 21 months (range 8-156). Location of nodal disease was pelvic in 4, paraaortic in 8, pelvic plus paraaortic in 4, inguinal in 4 and in the axilla in 1 of the patients. Median tumor size was 3 cm. CA-125 levels >35 U/ml were present in 13 cases. Complete cytoreduction was achieved in 17 (81%) and optimal (ConclusionIn selected patients presenting with ILNR optimal cytoreduction is possible in most of the cases with low perioperative morbidity. Combined with post-operative treatment, SCS results in a favorable outcome. More data are needed to better define the role of surgery in these patients.

29 keywords...

hide…